EGFR and neoplasm: When the tissue was detected as wild-type KRAS, the peripheral blood was detected as mutant-type KRAS. ctDNA analysis in vivo and in vitro assays have shown that by blocking the EGFR pathway, KRAS and NRAS mutations will occur rapidly, and mutations can usually be detected before imaging confirms tumor recurrence [101].